ClinicalTrials.gov
public full text
Public Domain
Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease
Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease#1072814
- Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease#853039
- Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients#854738
- Overnight Switch From Rasagiline To Safinamide#994959
- Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects#874759
Record · ID 1164027
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive